Xlife Sciences Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Xlife Sciences has been growing earnings at an average annual rate of 10.8%, while the Life Sciences industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 14.1% per year. Xlife Sciences's return on equity is 4.3%, and it has net margins of 2144.5%.
Belangrijke informatie
10.8%
Groei van de winst
4.3%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 17.6% |
| Inkomstengroei | 14.1% |
| Rendement op eigen vermogen | 4.3% |
| Nettomarge | 2,144.5% |
| Volgende winstupdate | 25 Apr 2025 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Xlife Sciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1 | 21 | 3 | 0 |
| 31 Mar 24 | 1 | 18 | 4 | 0 |
| 31 Dec 23 | 1 | 15 | 5 | 0 |
| 30 Sep 23 | 1 | 16 | 5 | 0 |
| 30 Jun 23 | 1 | 16 | 6 | 0 |
| 31 Mar 23 | 1 | 15 | 6 | 0 |
| 31 Dec 22 | 1 | 14 | 5 | 0 |
| 30 Sep 22 | 1 | 32 | 5 | 0 |
| 30 Jun 22 | 1 | 49 | 5 | 0 |
| 31 Mar 22 | 1 | 51 | 6 | 0 |
| 31 Dec 21 | 1 | 53 | 6 | 0 |
| 30 Sep 21 | 1 | 34 | 5 | 0 |
| 30 Jun 21 | 1 | 14 | 5 | 0 |
| 31 Mar 21 | 0 | 18 | 4 | 0 |
| 31 Dec 20 | 0 | 21 | 3 | 0 |
| 30 Sep 20 | 0 | 14 | 2 | 0 |
| 30 Jun 20 | 1 | 6 | 2 | 0 |
| 31 Mar 20 | 1 | 3 | 1 | 0 |
| 31 Dec 19 | 1 | 1 | 1 | 0 |
Kwaliteitswinsten: XLS has a large one-off gain of CHF38.6M impacting its last 12 months of financial results to 30th June, 2024.
Groeiende winstmarge: XLS's current net profit margins are higher than last year .
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: XLS's earnings have grown by 10.8% per year over the past 5 years.
Versnelling van de groei: XLS's earnings growth over the past year (31.7%) exceeds its 5-year average (10.8% per year).
Winst versus industrie: XLS earnings growth over the past year (31.7%) exceeded the Life Sciences industry 4.3%.
Rendement op eigen vermogen
Hoge ROE: XLS's Return on Equity (4.3%) is considered low.